Singapore markets close in 3 hours 2 minutes

Cellectis S.A. (CLLS)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
2.7300-0.1600 (-5.54%)
At close: 04:00PM EST

Cellectis S.A.

8, rue de la Croix Jarry
Paris 75013
France
33 1 81 69 16 00
https://www.cellectis.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees231

Key executives

NameTitlePayExercisedYear born
Dr. Andre Choulika Ph.D.Co-Founder, CEO & Director744.02kN/A1965
Dr. David J. D. Sourdive Ph.D.Deputy CEO, Executive VP of CMC & Manufacturing and Director528.92kN/A1967
Dr. Bing C. Wang M.B.A., Ph.D.Chief Financial OfficerN/AN/A1977
Valerie CrosPrincipal Financial Officer & Principal Accounting OfficerN/AN/AN/A
Mr. Jean Charles EpinatChief Technological OfficerN/AN/AN/A
Dr. Philippe Duchateau Ph.D.Chief Scientific OfficerN/AN/A1963
Mr. Stephan Reynier M.Sc.Chief Regulatory & Pharmaceutical Compliance OfficerN/AN/A1969
Ms. Marie-Bleuenn TerrierGeneral Counsel & Secretary of the Board of DirectorsN/AN/A1982
Pascalyne WilsonDirector of CommunicationsN/AN/AN/A
Ms. Kyung Nam-WortmanExecutive VP & Chief Human Resources OfficerN/AN/A1970
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Corporate governance

Cellectis S.A.’s ISS governance QualityScore as of 1 February 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 9; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.